Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Jul 2024

Seko Yuya, Yamaguchi Kanji, Shima Toshihide, Iwaki Michihiro, Takahashi Hirokazu, Kawanaka Miwa, Tanaka Saiyu, Mitsumoto Yasuhide, Yoneda Masato, Nakajima Atsushi, Okanoue Takeshi, Itoh Yoshito

Abstract excerpt

BACKGROUND & AIMS: PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 have been associated with an increased risk of liver-related events (LREs) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). In this study, we investigated the combined effects of these variants on LREs. METHODS: The longitudinal multicenter cohort study enrolled 1178 patients with biopsy-proven MASLD....

Read the complete abstract on PubMed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 17-Hydroxysteroid Dehydrogenases
Share to Acyltransferases
Share to Comorbidity
Share to Fatty Liver
Share to Lipase
Share to Liver Cirrhosis
Share to Longitudinal Studies
Share to Phospholipases A2, Calcium-Independent

Source

Identifiers

PMID: 38604296
DOI: 10.1016/j.cgh.2024.02.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease.PMID 38604296Read ↗

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver DiseaseSemantic proximity Read ↗

Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes.Semantic proximity Read ↗

Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver BiomarkersSemantic proximity Read ↗

Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population.Semantic proximity Read ↗

Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.Semantic proximity Read ↗

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.Semantic proximity Read ↗

Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.Semantic proximity Read ↗

Genetic Predisposition to MASLD: Potential for Therapeutic Management.Semantic proximity Read ↗

Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.